Jörg Hüser
YOU?
Author Swipe
View article: BAY-6096: A Potent, Selective, and Highly Water-Soluble Adrenergic α<sub>2B</sub> Antagonist
BAY-6096: A Potent, Selective, and Highly Water-Soluble Adrenergic α<sub>2B</sub> Antagonist Open
After acute myocardial infarction, early reperfusion is the most effective strategy for reducing cardiac damage and improving clinical outcome. However, restoring blood flow to the ischemic myocardium can paradoxically induce injury by its…
View article: Inhaled mosliciguat (BAY 1237592): targeting pulmonary vasculature via activating apo-sGC
Inhaled mosliciguat (BAY 1237592): targeting pulmonary vasculature via activating apo-sGC Open
Background Oxidative stress associated with severe cardiopulmonary diseases leads to impairment in the nitric oxide/soluble guanylate cyclase signaling pathway, shifting native soluble guanylate cyclase toward heme-free apo-soluble guanyla…
View article: Assessing the Use of the sGC Stimulator BAY-747, as a Potential Treatment for Duchenne Muscular Dystrophy
Assessing the Use of the sGC Stimulator BAY-747, as a Potential Treatment for Duchenne Muscular Dystrophy Open
Duchenne muscular dystrophy (DMD) is a severe and progressive muscle wasting disorder, affecting one in 3500 to 5000 boys worldwide. The NO-sGC-cGMP pathway plays an important role in skeletal muscle function, primarily by improving blood …
View article: Why translation from basic discoveries to clinical applications is so difficult for atrial fibrillation and possible approaches to improving it
Why translation from basic discoveries to clinical applications is so difficult for atrial fibrillation and possible approaches to improving it Open
Atrial fibrillation (AF) is the most common sustained clinical arrhythmia, with a lifetime incidence of up to 37%, and is a major contributor to population morbidity and mortality. Important components of AF management include control of c…
View article: Supplementary Material for: Effects of Finerenone Combined with Empagliflozin in a Model of Hypertension-Induced End-Organ Damage
Supplementary Material for: Effects of Finerenone Combined with Empagliflozin in a Model of Hypertension-Induced End-Organ Damage Open
Introduction: The nonsteroidal mineralocorticoid receptor (MR) antagonist finerenone and sodium-glucose cotransporter-2 (SGLT2) inhibitors have demonstrated clinical benefits in CKD patients with type 2 diabetes. Clinical data analyzing th…
View article: Telemetric hemodynamic assessment during anesthesia induction with propofol in experimental heart failure
Telemetric hemodynamic assessment during anesthesia induction with propofol in experimental heart failure Open
Standard error of the mean; BW: Body weight; Ntpro BNP: N terminal brain natriuretic peptide; EF: Ejection fraction; LVEDDV A4C: Left ventricular enddiastolic volume measured in four chamber view; LVLd A4C: Left ventricular length at diast…
View article: Effects of Finerenone Combined with Empagliflozin in a Model of Hypertension-Induced End-Organ Damage
Effects of Finerenone Combined with Empagliflozin in a Model of Hypertension-Induced End-Organ Damage Open
Introduction: The nonsteroidal mineralocorticoid receptor (MR) antagonist finerenone and sodium-glucose cotransporter-2 (SGLT2) inhibitors have demonstrated clinical benefits in CKD patients with type 2 diabetes. Clinical data analyzing th…
View article: Cardiac output improvement by pecavaptan: a novel dual‐acting vasopressin <scp>V1a/V2</scp> receptor antagonist in experimental heart failure
Cardiac output improvement by pecavaptan: a novel dual‐acting vasopressin <span>V1a/V2</span> receptor antagonist in experimental heart failure Open
Aims Arginine vasopressin (AVP) mediates deleterious effects via vascular V1a and renal V2 receptors in heart failure (HF). Despite positive short‐term decongestive effects in phase II HF studies, selective V2 receptor antagonism has shown…
View article: A New Therapeutic Framework for Atrial Fibrillation Drug Development
A New Therapeutic Framework for Atrial Fibrillation Drug Development Open
Atrial fibrillation (AF) is a highly prevalent cardiac arrhythmia and cause of significant morbidity and mortality. Its increasing prevalence in aging societies constitutes a growing challenge to global healthcare systems. Despite substant…
View article: Vascular Protection and Decongestion Without Renin–Angiotensin–Aldosterone System Stimulation Mediated by a Novel Dual-Acting Vasopressin V1a/V2 Receptor Antagonist
Vascular Protection and Decongestion Without Renin–Angiotensin–Aldosterone System Stimulation Mediated by a Novel Dual-Acting Vasopressin V1a/V2 Receptor Antagonist Open
Increased plasma vasopressin levels have been shown to be associated with the progression of congestive heart failure. Vasopressin mediates water retention by renal tubular V2 receptor activation as well as vasoconstriction, cardiac hypert…